Urology

Analysis of England’s urology waiting list found major reductions in long wait pathways between 2024 and 2026, while more than one third of pathways remained beyond 18 weeks.

A retrospective cohort study found longer progression-free survival and improved PSA responses with rezvilutamide plus ADT versus bicalutamide in high-volume mHSPC.

An 18-month feasibility trial found reduced uric acid stone volume with phentermine/topiramate in patients with obesity and diabetes, alongside metabolic and urinary changes.

A population level analysis found prostate cancer spending rose to $1.9 billion by 2021, with systemic therapy accounting for nearly three quarters of total expenditure.

Combined PRP and triamcinolone improved symptoms and bladder pain in patients with IC/BPS who had responded inadequately to previous PRP treatment.

A phase 3 trial found that Guang Jing significantly increased ureteral stone expulsion by day 28, with similar adverse event rates to placebo.

A large population analysis found that nocturia and urgency urinary incontinence identify distinct systemic health risks, while coexisting symptoms were associated with greater multimorbidity, depression, functional limitation, and mortality.

Robot-assisted kidney transplantation was associated with fewer major and vascular complications than open surgery, although neither difference was statistically significant.